Splice-switching oligonucleotides and methods of use
US12071626B2 · kind B2 · utility
0Cited by
2References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 1, 2021 |
| Grant date | Aug 27, 2024 |
| Priority date | — |
| Expiry date | Sep 9, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.